[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100553572":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":35,"locations":42,"responsibleParty":58,"collaborators":25,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":25,"eligibilityCriteria":66,"healthyVolunteers":67,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":25,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":83,"overallStatus":45,"whyStopped":25,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"University Hospital Tuebingen","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"GLP-1","EXPERIMENTAL","Acute administration of 0.25 mg semaglutide (0.19 ml)",[13],"Other: Subcutaneous GLP1-RA",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Acute administration of 0.19 ml NaCl",[19],"Other: Subcutaneous placebo",[21,26],{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"Subcutaneous GLP1-RA","Subcutaneous administration of semaglutide",[9],null,{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Subcutaneous placebo","Subcutaneous administration of NaCl",[15],[31],{"name":32,"affiliation":33,"role":34},"Andreas L. Birkenfeld, MD","Institute for Diabetes research and Metabolic Diseases at the University of Tubingen","STUDY_DIRECTOR",[36],{"name":37,"role":38,"phone":39,"phoneExt":40,"email":41},"Stephanie Kullmann, PhD","CONTACT","0049707129","87703","stephanie.kullmann@med.uni-tuebingen.de",[43],{"facility":44,"status":45,"city":46,"state":25,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"University Clinic Tubingen, Department of Internal Medicine IV","RECRUITING","Tübingen","72076","Germany","DE",{"type":51,"coordinates":52},"Point",[53,54],9.05222,48.52266,{"lat":54,"lon":53},[57],{"name":37,"role":38,"phone":39,"phoneExt":40,"email":41},{"type":59,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100553572","effect-of-glp1-receptor-agonist-on-brain-insulin-responsiveness-100553572",false,"NCT06487832","Effect of GLP1 Receptor Agonist on Brain Insulin Responsiveness","Impact of the Incretin System on Brain Insulin Sensitivity in Humans with Normal Weight, Overweight and Obesity","Inclusion Criteria:\n\n* BMI between 18.5 and 24.9 kg\u002Fm2; and between 27.5 kg\u002Fm2 and 40 kg\u002Fm2\n* Written consent to participate in the study\n* Written consent to be informed about incidental findings\n\nExclusion Criteria:\n\n* Type 1 or type 2 diabetes, LADA, MODY, or cardiovascular diseases such as chronic heart failure, myocardial infarction, status post stroke\n* BMI \\\u003C 18.5 or \\> 40 kg\u002Fm2\n* Persons who cannot legally give consent\n* Pregnancy or lactation\n* History of severe mental or somatic disorders including neurological diseases (incl. epileptic seizures)\n* Taking psychotropic drugs\n* Chronic diseases or medication that influence glucose metabolism\n* Regular use of analgesic drugs\n* Previous bariatric surgery\n* Known allergy against one or more of the used agents\n* Acute infection and\u002For antibiotic treatment within the last 4 weeks\n* Hemoglobin values less than 10.5 g\u002Fdl for women, less than 11.5 g\u002Fdl for men\n* Other diseases that in the opinion of the investigator may jeopardize the success of the study or indicate a risk to the volunteer\n* Participation in a lifestyle intervention study or a pharmaceutical study within the last 30 days\n* Metal implants which cannot be removed as pacemakers, artificial heart valve, electrical devices as insulin pumps, large tattoos, retainer over more than 4 teeth, contraceptive coil, implanted magnetic metal parts as screws or plates after a surgery\n* Persons with claustrophobia\n* Persons with tinnitus\n* Weight loss or gain of \\>5% in the last 3 months\n* Pancreatic diseases\n* History or family history of multiple endocrine neoplasia (MEN2) or medullary thyroid cancer\n* History of malignant thyroid disease\n* History of malignant disease in the past 5 years\n* Surgery in the last three months\n* Chronic tobacco use of more than 10 cigarettes\u002Fday\n* Women who do not consent to refrain from breastfeeding until 2 months after the end of the study\n* Women of childbearing age who do not consent to use safe method of contraception from 28 days before until 2 months after the end of the study or refrain from heterosexual intercourse during this time\n* Women of childbearing age who do not consent to take a pregnancy test",true,"ALL","18 Years","70 Years",{"count":72,"type":73},60,"ESTIMATED","INTERVENTIONAL",[76],"NA","The overarching goal of the current study is to investigate the effect of GLP-1 on brain insulin responsiveness in a randomized, single-blinded, within subject cross-over study design. To this end, investigators will compare the effect of the administration of semaglutide versus placebo, followed by an fMRI with administration of intranasal insulin or placebo.",[79,80,81,82],"Normal Weight","Overweight and Obesity","Insulin Sensitivity","Insulin Resistance",[9,84,85,86],"Brain","functional magnetic resonance imaging","Semaglutide","2025-03-25",{"date":89,"type":90},"2025-03-30","ACTUAL",{"date":92,"type":90},"2024-07-01",{"date":94,"type":73},"2027-12-31",{"name":5,"class":6},1]